1. DOP26 COVID-19 vaccine effectiveness in Inflammatory Bowel Disease patients on tumor-necrosis factor inhibitors: Real world data from a mass-vaccination campaign. (21st January 2022) Authors: Lev Zion, R; Focht, G; Lujan, R; Mendelovici, A; Friss, C; Greenfeld, S; Kariv, R; Ben-Tov, A; Matz, E; Nevo, D; Barak-Corren, Y; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i078 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP39 Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN. (27th May 2021) Authors: Atia, O; Yogev, D; Friss, C; Focht, G; Orlanski-Meyer, E; Magen Rimon, R; Ledderman, N; Greenfeld, S; Kariv, R; Loewenberg Weisband, Y; Gabay, H; Nevo, D; Matz, E; Gorelik, Y; Chowers, Y; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S077 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP44 Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRN. (27th May 2021) Authors: Magen Rimon, R; Atia, O; Friss, C; Ledderman, N; Greenfeld, S; Kariv, R; Loewenberg Weisband, Y; Gabay, C; Shaoul, R; Odes, S; Matz, E; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S081 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP46 Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohort. (27th May 2021) Authors: Atia, O; Friss, C; Mendelovici, A; Shteyer, E; Yogev, D; Ledderman, N; Greenfeld, S; Kariv, R; Loewenberg Weisband, Y; Gabay, H; Nevo, D; Matz, E; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DOP50 Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis. (27th May 2021) Authors: Ledder, O; Lujan, R; Orlanski-Meyer, E; Friss, C; Loewenberg Weisband, Y; Greenfeld, S; Kariv, R; Lederman, N; Matz, E; Focht, G; Yanai, H; Ollech, Y; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S085 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DOP58 predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN. (30th January 2023) Authors: Lujan, R; Atia, O; Gili, F; Greenfeld, S; Kariv, R; Loewenberg Weisband, Y; Lederman, N; Matz, E; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DOP61 Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes. (30th January 2023) Authors: Boaz, E; Ledder, O; Dagan, A; Lujan, R; Koslowsky, B; Friss, C; Greenfeld, S; Kariv, R; Loewenberg Weisband, Y; Lederman, N; Matz, E; Dotan, I; Yellinek, S; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DOP72 The association of anti-tumor necrosis factor and thiopurine therapy with the risk of lymphoma among Inflammatory Bowel Disease patients: A nation-wide study from the epi-IIRN. (21st January 2022) Authors: Waterman, M; Lavi, I; Harel, S; Focht, G; Loewenberg Weisband, J; Greenfeld, S; Kariv, R; Ledderman, N; Matz, E; Keinan-Boker, L; Eizenstein, S; Dotan, I; Turner, D; Levi, Z Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. DOP73 Antibiotic use differentially affects the risk of antidrug antibody formation during anti-TNFα therapy in Inflammatory Bowel Disease. (27th May 2021) Authors: Gorelik, Y; Freilich, S; Gerassy-Vainberg, S; Blatt, A; Pressman, S; Focht, G; Friss, C; Loewenberg Weisband, Y; Greenfeld, S; Kariv, R; Ledderman, N; Iris, D; Kashi, Y; Turner, D; Chowers, Y Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OP12 Does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRN. (30th January 2023) Authors: Focht, G; Lujan, R; Atia, O; Greenfeld, S; Kariv, R; Loewenberg Weisband, Y; Lederman, N; Matz, E; Dotan, I; Turner, D Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗